Capillary rarefaction of the coronary microcirculation is a consistent phenotype in patients with dialysisdependent ESRD (dd-ESRD) and may help explain their excess mortality. Global coronary flow reserve (CFR) assessed by positron emission tomography (PET) is a noninvasive, quantitative marker of myocardial perfusion and ischemia that integrates the hemodynamic effects of epicardial stenosis, diffuse atherosclerosis, and microvascular dysfunction. We tested whether global CFR provides risk stratification in patients with dd-ESRD. Consecutive patients with dd-ESRD clinically referred for myocardial perfusion PET imaging were retrospectively included, excluding patients with prior renal transplantation. Perpatient CFR was calculated as the ratio of stress to rest absolute myocardial blood flow. Multivariable Cox proportional hazards models, including age, overt cardiovascular disease, and myocardial scar/ischemia burden, were used to assess the independent association of global CFR with all-cause and cardiovascular mortality. The incremental value of global CFR was assessed with relative integrated discrimination index and net reclassification improvement. In 168 patients included, median global CFR was 1.4 (interquartile range, 1.2-1.8). During follow-up (median of 3 years), 36 patients died, including 21 cardiovascular deaths. Log-transformed global CFR independently associated with all-cause mortality (hazard ratio, 0.01 per 0.5-unit increase; 95% confidence interval, ,0.01 to 0.14; P,0.001) and cardiovascular mortality (hazard ratio, 0.01 per 0.5-unit increase; 95% confidence interval, ,0.01 to 0.15; P=0.002). For all-cause mortality, addition of global CFR resulted in risk reclassification in 27% of patients. Thus, global CFR may provide independent and incremental risk stratification for all-cause and cardiovascular mortality in patients with dd-ESRD.
Coronary flow reserve (CFR) as assessed by positron emission tomography (PET) is a quantitative, reproducible, and sensitive marker of myocardial perfusion and ischemia that integrates the hemodynamic effects of epicardial stenosis, diffuse atherosclerosis, and microvascular dysfunction. 7, 8 Addition of CFR has been shown to improve the value of traditional risk assessment for cardiac death in a variety of patient populations, including high-risk cohorts, such as patients with diabetes and patients with mild to moderate CKD. [9] [10] [11] [12] This study was designed to test the hypothesis that global CFR provides independent and incremental risk stratification in patients with dd-ESRD.
RESULTS

Baseline Characteristics
We identified 203 consecutive patients with dd-ESRD who underwent stress myocardial perfusion PETwith measurement of CFR during the study period. Two patients who had previously undergone heart transplantation and 33 patients who had previously undergone renal transplantation were excluded. The remaining 168 patients comprised the study cohort ( Table 1 ). The median age was 62 years old (interquartile range [IQR], 53-69), 39% of the patients were women, 61% of the cohort had diabetes, 93% had hypertension, and 43% had overt cardiovascular disease. The median left ventricular ejection fraction as assessed by PET was 52% (IQR, 44%-60%).
Coronary Hemodynamics
The median global myocardial blood flow (MBF) at rest was 1.1 (IQR, 0.9-1.4) ml/min per gram, which increased to 1.6 (IQR, 1.2-2.2) ml/min per gram during peak hyperemia. The corresponding median global CFR was 1.4 (IQR, 1.2-1.8). Figure 1 shows the high relative frequency of global CFR ,2.0 in this population, even in the absence of overt cardiovascular disease. As shown in Table 1 , rest MBF was similar in patients with global CFR above and below the cohort median value. Consequently, abnormalities in global CFR were driven primarily by diffusely impaired peak hyperemic MBF involving all three coronary artery territories. Supplemental Table 1 shows PET imaging parameters stratified by all-cause mortality during follow-up (primary endpoint).
All-Cause and Cardiovascular Mortality
During follow-up (median of 3 years), 36 all-cause deaths occurred (annual unadjusted mortality rate of 10%). The primary cause of death was cardiovascular in 21 patients, noncardiovascular in 11 patients, and unknown in four patients. All-cause mortality was significantly higher among patients with global CFR #1.4 than in those with global CFR .1.4 (logrank chi squared =15.5; P,0.001) (Figure 2A ). Cardiovascular mortality was also significantly higher among patients with CFR#1.4 than in those with CFR.1.4 (log-rank chi squared =12.3; P,0.001) ( Figure 2B ). Log-transformed global CFR was independently associated with all-cause mortality (hazard ratio, 0.01 per 0.5-unit increase; 95% confidence interval [95% CI], ,0.01 to 0.14; P,0.001) in a multivariable Cox proportional hazards model adjusting for age, overt cardiovascular disease, and myocardial scar/ischemia burden (Table 2, model 2). Additionally, log-transformed global CFR was independently associated with cardiovascular mortality (hazard ratio, 0.01 per 0.5-unit increase; 95% CI, ,0.01 to 0.15; P=0.002) in a multivariable Cox proportional hazards model adjusting for the same covariates as above (Table 3 , model 2). Medical etiology of CKD refers to CKD resulting primarily from hypertension, diabetes, and/or heart failure. Figure 1 . CFR,2.0 is highly prevalent in patients with dd-ESRD even in the absence of overt cardiovascular disease (CVD). Overt CVD was defined as one or more of prior myocardial infarction, stroke, percutaneous coronary intervention, coronary artery bypass, or peripheral arterial revascularization. 
Risk Reclassification by Global CFR
DISCUSSION
To our knowledge, this is the first study to link global CFR, a precise quantitative measure of coronary function and myocardial ischemia, to clinical outcomes in a large cohort of patients with dd-ESRD. We found that approximately 80% of patients in our cohort had global CFR values ,2.0, with values .2.0 considered to be low risk in other patient cohorts. 11 Importantly, we have also shown that global CFR provides risk stratification for all-cause and cardiovascular mortality independent of traditional risk factors, including age, known cardiovascular disease, and myocardial scar/ischemia burden. This novel finding highlights the significant clinical effect of diffuse atherosclerosis and microvascular dysfunction in this relatively understudied patient population. Finally, our results suggest a potentially important role of global CFR for risk reclassification in patients with dd-ESRD, generally assumed until now to be at uniformly high risk for mortality.
Exactly how impaired global CFR associates with increased clinical risk cannot be determined from this study. Two potential mechanisms could, however, explain our findings. First, impaired global CFR may result from significant myocardial capillary rarefaction, a well known phenomenon in patients with dd-ESRD. 4 In experimental uremic rat models, myocardial capillary rarefaction has been associated with increased myocardial ischemia and myocardial infarct size. 6 Myocardial ischemia resulting from supply-demand mismatch may lead to low-level myocardial injury and regional wall motion abnormalities and may explain the association between elevated high-sensitivity cardiac troponin T and incident heart failure in patients with dd-ESRD without coronary artery disease. 13, 14 Second, impaired global CFR may also reflect microvascular dysfunction resulting from arteriolar remodeling, 15 endothelial dysfunction, and/or increased extravascular resistance (i.e., left ventricular hypertrophy or interstitial fibrosis), all of which have been documented in patients with uremia 16 and may be contributors to subclinical myocardial ischemia and injury.
Our results support the hypothesis that diffuse atherosclerosis and microvascular dysfunction, as measured by global CFR, are important markers of clinical risk in patients with dd-ESRD and that quantitation of global CFR may be a clinically useful tool to improve risk stratification in these patients. 16 Diffuse atherosclerosis and microvascular dysfunction may partially explain why the association between elevated LDL cholesterol and myocardial infarction is attenuated in patients with advanced CKD 17 and may also help us understand previously observed discrepancies between traditional cardiovascular risk assessment and outcomes after renal transplantation. 18 Additional studies are needed to determine whether longitudinal improvement in global CFR is associated with risk reduction. If that can be shown, it may be appropriate to use global CFR as a surrogate for mortality in future clinical trials involving patients with dd-ESRD.
As with any diagnostic test, the potential benefits of measuring global CFR should be weighed against the associated risks. The radiation dose associated with PET myocardial perfusion imaging is approximately 4.6 millisievert (mSv) or less depending on the protocol and radiopharmaceutical dose. This is generally considered low-level radiation, which is slightly higher than the 3-mSv dose from background radiation in the United States. However, any CFR-based risk stratification strategy should always be weighed against alternative strategies that do not require radiation exposure.
Our study is subject to limitations inherent to a singlecenter, retrospective study design, including higher-risk patients clinically referred for evaluation of symptoms or as part of prerenal transplant evaluation. Consequently, our results should be extrapolated to other populations with caution, particularly the subset of patients with dd-ESRD not referred for cardiovascular risk stratification. Nevertheless, with limited exclusion criteria, we believe that our study cohort is fairly representative of patients with dd-ESRD clinically referred for cardiovascular risk stratification at most large medical centers.
A second limitation is that we were unable to rigorously characterize the duration of CKD and dialysis before CFR evaluation. Future studies that do so could more precisely illuminate the effects of CKD and dialysis on CFR. A third consideration is that all patients in our cohort were tested during the interdialytic interval. Whether volume shifts during this period affect global CFR and/or its association with mortality cannot be determined from our data. However, consistent evidence from experimental animals and humans suggests that endothelium-dependent or -independent coronary vasodilatory function is not affected by volume overload. [19] [20] [21] Finally, our sample size limited the number of confounding variables that we could adjust for in our multivariable Cox survival analyses and may have limited our power to detect weak associations of baseline characteristics with global CFR.
In summary, our study is the first to show that global CFR provides independent and incremental risk stratification in patients with dd-ESRD. A relatively preserved global CFR helps identify patients with dd-ESRD at significantly lower clinical risk, and as such, it may be an appropriate surrogate end point in future clinical trials involving this high-risk population.
CONCISE METHODS
Study Sample
Consecutive patients with dd-ESRD clinically referred for stress myocardial perfusion PET imaging at the Brigham and Women's Hospital between January 1, 2006 and November 30, 2012 were retrospectively included in the study cohort. Patients were referred for evaluation of known or suspected coronary artery disease and/or 
PET Imaging
Patients were studied using a whole-body PET-computed tomography scanner (Discovery RX or STE Lightspeed 64; GE Healthcare, Milwaukee, WI). Myocardial perfusion was assessed at rest and during peak hyperemia using 82 Rb or 13 N-ammonia as the flow tracer, which has been described previously. 11 Hyperemic stress was achieved using intravenous dipyridamole, adenosine, or regadenoson as per standard protocol. Prior data have shown equivalence in the hyperemia achieved with these agents and more importantly, no agent-specific effect on the association between global CFR and patient outcomes. 11, 22 To ensure stability of intravascular volume and serum electrolytes, it is standard practice in our nuclear cardiology laboratory not to administer intravenous vasodilator stress agents on the day of dialysis. CFR measurements are obtained through postprocessing of PET images and therefore, do not involve additional radiation exposure, imaging time, or cost to the patient. Computed tomography was used only for attenuation correction. The average radiation exposure for the entire PET study was #4.6 mSv. For semiquantitative assessment of myocardial scarring and ischemia, 17-segment visual interpretation of gated myocardial perfusion images was performed by experienced operators using a standard five-point scoring system. 23 Global rest, stress, and difference (stress 2 rest) scores reflecting the total left ventricular burden of ischemia and/or scar were converted to percentage of myocardium by dividing by the maximum score of 68. For each of these variables, higher scores reflect larger areas of myocardial scar and/or ischemia. Rest and stress left ventricular ejection fractions were calculated from gated myocardial perfusion images using commercially available software (4DM; Invia, Ann Arbor, MI).
Absolute global MBF (in milliliters per minute per gram) was quantified at rest and peak hyperemia using automated factor analysis and a validated two-compartment kinetic model as previously described. 24 Per-patient global CFR was calculated as the ratio of stress to rest absolute MBF for the entire left ventricle. MBF and CFR values were not clinically available to referring physicians.
Outcomes
The prespecified primary end point was all-cause mortality. Vital status was ascertained by integrating data from the Social Security Death Index, the National Death Index, and the Partners Healthcare Research Patient Data Registry. Secondary analysis was performed for cardiovascular mortality. Cause of death was determined by blinded adjudication by two independent cardiologists as described previously. 25 
Statistical Analyses
Statistical significance was assessed with Wilcoxon tests, Fisher exact tests, and chi-squared tests for continuous, dichotomous, and categorical variables, respectively. Two-sided P values ,0.05 were considered significant. Cox proportional hazards models were used to assess the association of global CFR with all-cause and cardiovascular mortality after controlling for age, overt cardiovascular disease, and myocardial scar/ischemia burden. Because global CFR followed a log-normal distribution, it was transformed with the natural log before inclusion in the Cox models. Patients who underwent renal transplantation after PET were censored on the date of transplantation. Incremental value of global CFR was assessed with the global chi squared statistic for improved model fit, relative IDI for risk discrimination, and NRI for risk reclassification; 95% CIs for NRI were determined by bootstrapping. We used risk categories of ,1%, 1%-3%, and .3% per year risk of mortality for the categorical NRI. All statistical analyses were performed with Stata, version 13 (StataCorp LP, College Station, TX), SAS, version 9.4 (SAS Institute, Cary, NC), or R 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria).
